St Jude completes Velocimed acquisition:
This article was originally published in Clinica
St Jude Medical has completed its acquisition of interventional cardiology firm Velocimed. It is paying $74m in cash plus contingent payments, and will record a special charge of about $13.8m in the second quarter related to in-process R&D. The deal was announced on February 15, and was for $82.5m in total, minus an estimated $8.5m in cash at Velocimed, of Maple Grove, Minnesota.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.